Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance

• Status: Not yet recruiting
• Trial end date: 2029-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this randomized, pragmatic clinical trial is to evaluate an endocrine therapy dose-frequency escalation strategy and its effects on tolerability and compliance. Participants will be randomized to standard daily dosing of endocrine therapy or endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute

Criteria

Inclusion Criteria:

• Patients with an early stage or locally advanced hormonal receptor positive breast cancer

• Plan to receive endocrine therapy

• Able to provide oral consent

• Willing and able to complete questionnaires as per study protocol

Exclusion Criteria:

• Metastatic cancer

• Adjuvant abemaciclib